-
3
-
-
84953856186
-
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the openlabel, phase 3 TRIBE study
-
Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the openlabel, phase 3 TRIBE study. Lancet Oncol 2015;16: 1306-1315.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1306-1315
-
-
Cremolini, C.1
Loupakis, F.2
Antoniotti, C.3
-
4
-
-
84920954757
-
FOLFOXIRI and bevacizumab formetastatic colorectal cancer
-
Cremolini C, Loupakis F, Falcone A. FOLFOXIRI and bevacizumab formetastatic colorectal cancer. N Engl JMed 2015;372:291-292.
-
(2015)
N Engl Jmed
, vol.372
, pp. 291-292
-
-
Cremolini, C.1
Loupakis, F.2
Falcone, A.3
-
5
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumabas first-line treatment for patientswithmetastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
-
Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumabas first-line treatment for patientswithmetastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-1075.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
Von Weikersthal, L.F.2
Decker, T.3
-
6
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369: 1023-1034.
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
-
7
-
-
84903694472
-
Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
-
Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25: 1346-1355.
-
(2014)
Ann Oncol
, vol.25
, pp. 1346-1355
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
-
8
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
-
9
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, Köhne C-H, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
van Cutsem, E.1
Köhne, C.-H.2
Láng, I.3
-
10
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl JMed 2008;359: 1757-1765.
-
(2008)
N Engl Jmed
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
-
11
-
-
79956310674
-
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
-
Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 2011; 22:1535-1546.
-
(2011)
Ann Oncol
, vol.22
, pp. 1535-1546
-
-
Bokemeyer, C.1
Bondarenko, I.2
Hartmann, J.T.3
-
12
-
-
84908431348
-
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
-
Misale S, Di Nicolantonio F, Sartore-Bianchi A et al. Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-1280.
-
(2014)
Cancer Discov
, vol.4
, pp. 1269-1280
-
-
Misale, S.1
Di Nicolantonio, F.2
Sartore-Bianchi, A.3
-
13
-
-
79957523828
-
KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
-
De Roock W, De Vriendt V, Normanno N et al. KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603.
-
(2011)
Lancet Oncol
, vol.12
, pp. 594-603
-
-
de Roock, W.1
de Vriendt, V.2
Normanno, N.3
-
14
-
-
77955046517
-
Genomic and biological characterization of exon 4 KRA Smutations in human cancer
-
Janakiraman M, Vakiani E, Zeng Z et al. Genomic and biological characterization of exon 4 KRA Smutations in human cancer. Cancer Res 2010; 70:5901-5911.
-
(2010)
Cancer Res
, vol.70
, pp. 5901-5911
-
-
Janakiraman, M.1
Vakiani, E.2
Zeng, Z.3
-
15
-
-
84964314170
-
Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer
-
Morris VK, Lucas FAS, Overman MJ et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 2014;25: 2008-2014.
-
(2014)
Ann Oncol
, vol.25
, pp. 2008-2014
-
-
Morris, V.K.1
Lucas, F.2
Overman, M.J.3
-
16
-
-
68749119351
-
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer
-
Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer. Br J Cancer 2009;101:715-721.
-
(2009)
Br J Cancer
, vol.101
, pp. 715-721
-
-
Loupakis, F.1
Ruzzo, A.2
Cremolini, C.3
-
17
-
-
84995461857
-
-
Accessed June 8, 2016
-
NCCN Guidelines v.3.2015. Available at https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 8, 2016.
-
-
-
-
18
-
-
84942868219
-
Molecular pathways: Sensitivity and resistance to anti-EGFR antibodies
-
Bertotti A, Sassi F. Molecular pathways: Sensitivity and resistance to anti-EGFR antibodies. Clin Cancer Res 2015;21:3377-3383.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 3377-3383
-
-
Bertotti, A.1
Sassi, F.2
-
19
-
-
84936748494
-
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
-
Siravegna G, Mussolin B, Buscarino M et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015;21:795-801.
-
(2015)
Nat Med
, vol.21
, pp. 795-801
-
-
Siravegna, G.1
Mussolin, B.2
Buscarino, M.3
-
20
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-762.
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
de Roock, W.1
Claes, B.2
Bernasconi, D.3
-
21
-
-
59049089201
-
PI3KCA/ PTEN deregulation contributes to impaired responses to cetuximab inmetastatic colorectal cancer patients
-
Perrone F, Lampis A, Orsenigo M et al. PI3KCA/ PTEN deregulation contributes to impaired responses to cetuximab inmetastatic colorectal cancer patients. Ann Oncol 2009;20:84-90.
-
(2009)
Ann Oncol
, vol.20
, pp. 84-90
-
-
Perrone, F.1
Lampis, A.2
Orsenigo, M.3
-
22
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
23
-
-
84944079826
-
The genomic landscape of response to EGFR blockade in colorectal cancer
-
Bertotti A, Papp E, Jones S et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526:263-267.
-
(2015)
Nature
, vol.526
, pp. 263-267
-
-
Bertotti, A.1
Papp, E.2
Jones, S.3
-
24
-
-
84887491073
-
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
-
Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
-
(2013)
Nat Biotechnol
, vol.31
, pp. 1023-1031
-
-
Frampton, G.M.1
Fichtenholtz, A.2
Otto, G.A.3
-
25
-
-
84995509582
-
Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP)
-
Hall MJ, Gowen K, Sanford E M et al. Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP). J Clin Oncol 2016; 34(suppl 4S):528a.
-
(2016)
J Clin Oncol
, vol.34
, pp. 528
-
-
Hall, M.J.1
Gowen, K.2
Sanford, E.M.3
-
26
-
-
12144289677
-
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
-
Wan PTC, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116: 855-867.
-
(2004)
Cell
, vol.116
, pp. 855-867
-
-
Wan, P.1
Garnett, M.J.2
Roe, S.M.3
-
27
-
-
84879240684
-
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
-
Valtorta E, Misale S, Sartore-Bianchi A et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013;133:1259-1265.
-
(2013)
Int J Cancer
, vol.133
, pp. 1259-1265
-
-
Valtorta, E.1
Misale, S.2
Sartore-Bianchi, A.3
-
28
-
-
79958796709
-
Biomarker-based selection of therapy for colorectal cancer
-
Ross JS. Biomarker-based selection of therapy for colorectal cancer. Biomarkers Med 2011;5: 319-332.
-
(2011)
Biomarkers Med
, vol.5
, pp. 319-332
-
-
Ross, J.S.1
-
29
-
-
84932606172
-
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
-
Arena S, Bellosillo B, Siravegna G et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015;21:2157-2166.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2157-2166
-
-
Arena, S.1
Bellosillo, B.2
Siravegna, G.3
-
30
-
-
84931364786
-
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
-
Braig F, März M, Schieferdecker A et al. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget 2015;6: 12035-12047.
-
(2015)
Oncotarget
, vol.6
, pp. 12035-12047
-
-
Braig, F.1
März, M.2
Schieferdecker, A.3
-
31
-
-
84856717005
-
Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer [published correction appears in Nat Med 2012;18:1445]
-
Montagut C, Dalmases A, Bellosillo B et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer [published correction appears in Nat Med 2012;18:1445]. Nat Med 2012;18:221-223.
-
(2012)
Nat Med
, vol.18
, pp. 221-223
-
-
Montagut, C.1
Dalmases, A.2
Bellosillo, B.3
-
32
-
-
84878862323
-
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
-
Bardelli A, Corso S, Bertotti A et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-673.
-
(2013)
Cancer Discov
, vol.3
, pp. 658-673
-
-
Bardelli, A.1
Corso, S.2
Bertotti, A.3
-
33
-
-
80052591747
-
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
-
Yonesaka K, Zejnullahu K, Okamoto I et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
-
(2011)
Sci Transl Med
, vol.3
-
-
Yonesaka, K.1
Zejnullahu, K.2
Okamoto, I.3
-
34
-
-
84939181687
-
HER2activating mutations are targets for colorectal cancer treatment
-
Kavuri SM, Jain N, Galimi F et al. HER2activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015;5:832-841.
-
(2015)
Cancer Discov
, vol.5
, pp. 832-841
-
-
Kavuri, S.M.1
Jain, N.2
Galimi, F.3
-
35
-
-
84933040790
-
Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer throughMAPK pathway alterations
-
Ahronian LG, Sennott EM, Van Allen EM et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer throughMAPK pathway alterations. Cancer Discov 2015;5:358-367.
-
(2015)
Cancer Discov
, vol.5
, pp. 358-367
-
-
Ahronian, L.G.1
Sennott, E.M.2
van Allen, E.M.3
-
36
-
-
84903301924
-
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
-
Therkildsen C, Bergmann TK, Henrichsen-Schnack T et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53:852-864.
-
(2014)
Acta Oncol
, vol.53
, pp. 852-864
-
-
Therkildsen, C.1
Bergmann, T.K.2
Henrichsen-Schnack, T.3
-
37
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies
-
Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res 2009; 69:1851-1857.
-
(2009)
Cancer Res
, vol.69
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
Martini, M.2
Molinari, F.3
-
38
-
-
73349094741
-
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wildtype KRAS metastatic colon cancer
-
Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wildtype KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-5930.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5924-5930
-
-
Laurent-Puig, P.1
Cayre, A.2
Manceau, G.3
-
39
-
-
84962298279
-
Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF
-
Hechtman JF, Zehir A, Yaeger R et al. Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF. Mol Cancer Res 2016;14:296-301.
-
(2016)
Mol Cancer Res
, vol.14
, pp. 296-301
-
-
Hechtman, J.F.1
Zehir, A.2
Yaeger, R.3
-
40
-
-
84958551355
-
Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
-
Disel U, Germain A, Yilmazel B et al. Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. Oncoscience 2015; 2:581-584.
-
(2015)
Oncoscience
, vol.2
, pp. 581-584
-
-
Disel, U.1
Germain, A.2
Yilmazel, B.3
-
41
-
-
84995437954
-
Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors
-
Hurwitz H, Hainsworth JD, Swanton C et al. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. J Clin Oncol 2016;34(suppl 4S):653a.
-
(2016)
J Clin Oncol
, vol.34
, pp. 653
-
-
Hurwitz, H.1
Hainsworth, J.D.2
Swanton, C.3
-
42
-
-
84929575728
-
Clinical response to sorafenib in a patient with metastatic colorectal cancer and FLT3 amplification
-
Moreira RB, Peixoto RD, de Sousa Cruz MR. Clinical response to sorafenib in a patient with metastatic colorectal cancer and FLT3 amplification. Case Rep Oncol 2015;8:83-87.
-
(2015)
Case Rep Oncol
, vol.8
, pp. 83-87
-
-
Moreira, R.B.1
Peixoto, R.D.2
de Sousa Cruz, M.R.3
-
43
-
-
84957063275
-
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer
-
Russo M, Siravegna G, Blaszkowsky LS et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov 2016;6:147-153.
-
(2016)
Cancer Discov
, vol.6
, pp. 147-153
-
-
Russo, M.1
Siravegna, G.2
Blaszkowsky, L.S.3
-
44
-
-
85011961061
-
BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy
-
Klempner SJ, Gershenhorn B, Tran P et al. BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy. Cancer Discov 2016;6:594-600.
-
(2016)
Cancer Discov
, vol.6
, pp. 594-600
-
-
Klempner, S.J.1
Gershenhorn, B.2
Tran, P.3
-
45
-
-
84958078144
-
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
-
Arena S, Siravegna G, Mussolin B et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med 2016;8:324ra14.
-
(2016)
Sci Transl Med
, vol.8
-
-
Arena, S.1
Siravegna, G.2
Mussolin, B.3
-
46
-
-
84979992202
-
Oncogenic ALK Fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target
-
Yakirevich E, Resnick MB, Mangray S et al. Oncogenic ALK Fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. Clin Cancer Res 2016;22:3831-3840.
-
(2016)
Clin Cancer Res
, vol.22
, pp. 3831-3840
-
-
Yakirevich, E.1
Resnick, M.B.2
Mangray, S.3
-
47
-
-
84954060726
-
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer
-
Russo M, Misale S, Wei G et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov 2016;6:36-44.
-
(2016)
Cancer Discov
, vol.6
, pp. 36-44
-
-
Russo, M.1
Misale, S.2
Wei, G.3
-
48
-
-
84945152069
-
Identification and characterization of RET fusions in advanced colorectal cancer
-
Le Rolle A-F, Klempner SJ, Garrett CR et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 2015;6: 28929-28937.
-
(2015)
Oncotarget
, vol.6
, pp. 28929-28937
-
-
Le Rolle, A.-F.1
Klempner, S.J.2
Garrett, C.R.3
-
49
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
-
50
-
-
77449130761
-
Microsatellite instability in colorectal cancer
-
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138: 2073-2087.e3.
-
Gastroenterology 2010
, vol.138
, pp. 2073-2087
-
-
Boland, C.R.1
Goel, A.2
-
51
-
-
84973622902
-
Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in nextgeneration sequencing panels
-
Stadler ZK, Battaglin F, Middha S et al. Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in nextgeneration sequencing panels. J Clin Oncol 2016;34: 2141-2147.
-
(2016)
J Clin Oncol
, vol.34
, pp. 2141-2147
-
-
Stadler, Z.K.1
Battaglin, F.2
Middha, S.3
-
52
-
-
84954202031
-
Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015
-
Allegra CJ, Rumble RB, Hamilton SR et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol 2016;34:179-185.
-
(2016)
J Clin Oncol
, vol.34
, pp. 179-185
-
-
Allegra, C.J.1
Rumble, R.B.2
Hamilton, S.R.3
-
53
-
-
12644273250
-
Biochemical characterization of a novel KRAS insertion mutation from a human leukemia
-
Bollag G, Adler F, elMasry N et al. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem 1996;271:32491-32494.
-
(1996)
J Biol Chem
, vol.271
, pp. 32491-32494
-
-
Bollag, G.1
Adler, F.2
Elmasry, N.3
-
54
-
-
84901710704
-
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer
-
Tong JHM, Lung RWM, Sin FMC et al. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther 2014; 15:768-776.
-
(2014)
Cancer Biol Ther
, vol.15
, pp. 768-776
-
-
Tong, J.1
Lung, R.2
Sin, F.3
-
55
-
-
84896118508
-
KRAS insertions in colorectal cancer: What do we know about unusual KRAS mutations?
-
de Macedo MP, de Lima LGCA, Begnami MDFS et al. KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations? Exp Mol Pathol 2014;96:257-260.
-
(2014)
Exp Mol Pathol
, vol.96
, pp. 257-260
-
-
de Macedo, M.P.1
de Lima, L.2
Begnami, M.3
-
56
-
-
47749128875
-
KRAS mutation profile in colorectal carcinoma and novelmutation-internal tandem duplication in KRAS
-
Wójcik P, Kulig J, Okón K et al. KRAS mutation profile in colorectal carcinoma and novelmutation-internal tandem duplication in KRAS. Pol J Pathol 2008;59:93-96.
-
(2008)
Pol J Pathol
, vol.59
, pp. 93-96
-
-
Wójcik, P.1
Kulig, J.2
Okón, K.3
-
57
-
-
84877130883
-
Effect of low-frequency KRASmutations on the response to anti-EGFR therapy in metastatic colorectal cancer
-
Tougeron D, Lecomte T, Pagès JC et al. Effect of low-frequency KRASmutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013;24:1267-1273.
-
(2013)
Ann Oncol
, vol.24
, pp. 1267-1273
-
-
Tougeron, D.1
Lecomte, T.2
Pagès, J.C.3
-
58
-
-
84895060068
-
KRAS testing in metastatic colorectal carcinoma: Challenges, controversies, breakthroughs and beyond
-
Malapelle U, Carlomagno C, de Luca C et al. KRAS testing in metastatic colorectal carcinoma: Challenges, controversies, breakthroughs and beyond. J Clin Pathol 2014;67:1-9.
-
(2014)
J Clin Pathol
, vol.67
, pp. 1-9
-
-
Malapelle, U.1
Carlomagno, C.2
de Luca, C.3
|